Vaccination in HIV positive adults: need to address

Hum Vaccin Immunother. 2014;10(10):3011-2. doi: 10.4161/21645515.2014.971645.

Abstract

Human Immunodeficiency Virus (HIV) continues to be a major public health program. Without treatment, average survival time without treatment after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. Vaccination recommendations are determined by weighing the benefits of vaccination against the risks. It is preferable to have patients on antiretroviral therapy (ART) prior to receipt of vaccination, as that may help blunt or eliminate vaccine-associated viremia and potentially improve immune response to vaccination. : Although data are limited, in general, HIV-infected individuals who are on ART with well-controlled HIV RNA levels and CD4 counts of >200 cells/μL (or = 15%) may receive indicated live-virus vaccines. Vaccination can play a vital role in enhancing the immunity against opportunistic infections. Further research, is the need for a better and healthy living of the people with HIV.

Keywords: AIDS; HIV; immunity; opportunistic infections; vaccination.

MeSH terms

  • AIDS-Related Opportunistic Infections / prevention & control*
  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • Humans
  • Vaccination / adverse effects
  • Vaccination / methods*
  • Vaccines / administration & dosage*
  • Viral Load
  • Viremia / prevention & control*

Substances

  • Anti-HIV Agents
  • Vaccines